相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2009
已完成
2
50.0%
招募中
1
25.0%
Unknown
1
25.0%
暂无批准数据
- Lipidor AB has announced that half of the patients have been randomized in its Phase III clinical study of AKP02G2 for mild to moderate psoriasis. - The study, involving 294 patients across 15 clinics, compares AKP02G2 to a market-leading psoriasis treatment. - Patient recruitment is expected to be completed in February, with topline results anticipated in April 2025. - The company's CEO, Ola Holmlund, noted that reaching the halfway mark is a significant milestone, with all clinics now actively recruiting.
- Lipidor AB has enrolled the first patient in its Phase III clinical trial evaluating AKP02G2, a topical spray for mild to moderate psoriasis. - AKP02G2 combines calcipotriol and betamethasone, utilizing Lipidor's AKVANO technology, aiming for efficacy comparable to Enstilar. - The Phase III study, managed by Cliantha, plans to enroll 294 patients to assess AKP02G2's effectiveness and patient-friendliness. - AKP02G2 seeks to provide a fast-drying, easy-to-use treatment option for psoriasis patients, potentially improving adherence and outcomes.
